Synlogic (SYBX) Q4 2024 earnings summary

Executive summary

• Discontinued lead Phase 3 trial (Synpheny-3) for SYNB1934 in PKU after internal review indicated unlikely success; focus shifted to strategic alternatives including merger or sale.

• Workforce reduced to one full-time employee; restructuring and asset sales implemented to conserve cash and support strategic review.

• Early-stage pipeline for HCU, enteric hyperoxaluria, and gout remains, but future R&D is uncertain pending outcome of strategic review.

Financial highlights

• Net loss for 2024 was $23.4 million, a significant improvement from $61.3 million in 2023, driven by lower R&D and G&A expenses.

• Revenue dropped to $8,000 in 2024 from $3.4 million in 2023, reflecting the end of the Roche collaboration.

• Cash and cash equivalents at year-end 2024 were $18.9 million, down from $24.0 million at year-end 2023.

• Restructuring and other charges totaled $25.2 million in 2024, including severance, asset impairments, and contract terminations.

• Other income of $17.6 million in 2024 was primarily due to a gain from the change in fair value of purchase warrant liabilities.

Outlook and guidance

• Expenses expected to decrease in the near term due to halted clinical development and workforce reductions.

• Current cash position expected to fund operations for at least the next 12 months while strategic alternatives are pursued.

• No product revenue anticipated unless a strategic transaction is completed or development resumes.